Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Scafetta Roberta, Donato Marco, Gullotta Carla, Guarino Alessandra, Fiore Cristina, Sisca Luisana, Speziale Elena, Troiano Raffaella, Foderaro Simone, Venuti Fabio, Vilardi Francesco Antonio, Ricozzi Valentina, Iuliani Michele, Simonetti Sonia, Cavaliere Silvia, Cortellini Alessio, La Cesa Annalisa, Botticelli Andrea, Scagnoli Simone, Pisegna Simona, Criscitiello Carmen, Chirco Alessandra, D'Alessandro Sara, Pedersini Rebecca, Sposetti Caterina, Tiberi Elisa, D'Auria Giuliana, Vergati Matteo, Mazzotta Marco, Caputo Roberta, Verrazzo Annarita, Rossino Maria Grazia, Domati Federica, Piombino Claudia, Di Lisa Francesca Sofia, Filomeno Lorena, Arcuri Teresa, Puce Federica, Riva Federica, Palleschi Michela, Sirico Marianna, Piras Marta, Stucci Luigia Stefania, De Lisi Delia, Orsaria Paolo, Grasso Antonella, Ippolito Edy, Ramella Sara, Visani Luca, Bertini Niccolò, Bonaparte Ilaria, Gori Stefania, Rossi Luigi, Meattini Icro, Tagliaferri Barbara, Caffo Orazio, Bonomo Maria Vittoria, Portarena Ilaria, Irelli Azzurra, Cretella Elisabetta, Porta Camillo, Bianchini Giampaolo, Fabbri Maria Agnese, De Giorgi Ugo, Vici Patrizia, Toss Angela, Garrone Ornella, De Laurentiis Michelino, Villa Federica, Berardi Rossana, Minelli Mauro, Altomare Vittorio, Vernieri Claudio, Curigliano Giuseppe, Vincenzi Bruno, Tonini Giuseppe, Santini Daniele, Pantano Francesco
Аннотация
METHODS: This retrospective, multicenter cohort study (January 2019-December 2023; median follow-up 39 months) evaluated the real-world progression-free survival (rwPFS) of abemaciclib, ribociclib, and palbociclib combined with endocrine therapy (ET) in HR+/HER2- mBC patients with bone metastases. Overall survival (OS) was a secondary exploratory endpoint. A total of 1399 patients with ECOG PS 0-1 and at least 12 months of follow-up were included. Analyses used propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) to adjust for confounding.
RESULTS: Palbociclib showed shorter rwPFS (22 months) compared to abemaciclib (32 months; HR = 1.47, p = 0.001) and ribociclib (35 months; HR = 1.49, p < 0.001). No significant difference was observed between abemaciclib and ribociclib. OS was also lower with palbociclib (47 months) versus abemaciclib (60 months; HR = 1.77, p < 0.001) and ribociclib (64 months; HR = 1.69, p = 0.001). Results were consistent after PSM and IPTW adjustment.
CONCLUSION: Ribociclib and abemaciclib may provide superior rwPFS and OS compared to palbociclib in HR+/HER2- mBC patients with bone metastases.